Natural Products for the Treatment of Type 2 Diabetes Mellitus

Planta Medica

Volumn 81, Issue 12-13, 2015, Pages 975-994

  Ríos, José Luis ^a   Francini, Flavio ^b   Schinella, Guillermo R ^c,d  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

^c FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^d Comisión de Investigaciones Científicas de la Provincia de Buenos Aires ^*  (Argentina)

Author keywords

antidiabetic; clinical trials; diabetes; medicinal plants

Indexed keywords

ALPHA GLUCOSIDASE; AMYLASE; GLUCOSE TRANSPORTER; NATURAL PRODUCT; ANTIDIABETIC AGENT; BIOLOGICAL PRODUCT; GLUCOSE BLOOD LEVEL; GLYCOSIDASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ALOE; ANTIDIABETIC ACTIVITY; CACAO; CELL PROLIFERATION; CINNAMON; COFFEE; ENZYME INHIBITION; FENUGREEK; GARLIC; GLUCOSE ABSORPTION; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GUAVA; GYMNEMA; HUMAN; ILEX PARAGUARIENSIS; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN SENSITIVITY; MEDICINAL PLANT; MOMORDICA CHARANTIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PHYTOTHERAPY; REVIEW; SOYBEAN; TEA; UPREGULATION; WALNUT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; METABOLISM;

ALLIUM SATIVUM; ALOE; CAMELLIA SINENSIS; CAPPARIS SPINOSA; CINNAMOMUM VERUM; CROTON OVALIFOLIUS; CUCUMIS; CURCUMA LONGA; GALEGA OFFICINALIS; GLYCINE MAX; GYMNEMA; JUGLANS; PSIDIUM; THEOBROMA CACAO; TRIGONELLA FOENUM-GRAECUM; URTICA;

ALPHA-AMYLASES; ALPHA-GLUCOSIDASES; BIOLOGICAL PRODUCTS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PLANTS, MEDICINAL;

EID: 84939652973     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0035-1546131     Document Type: Review

References (197)

1. Klonoff D. C., Schwartz D. M. An economic analysis of interventions for diabetes. Diabetes Care: 2000; 23 390 404
2. King H., Aubert R. E., Herman W. H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care: 1998; 21 1414 1431
3. ADA, American Diabetes Association Standards of medical care in diabetes - 2014. Diabetes Care: 2014; 37 S14 S80
4. ADA, American Diabetes Association Clinical practice recommendations 2007. Diabetes Care: 2007; 30 S3
5. LADA, Latin American Diabetes Association Guías ALAD de diagnóstico control y tratamiento de la diabetes mellitus tipo 2. Ver Asoc Latinoam Diabetes: 2006; 14 3 4
6. Fall C. H. Non-industrialised countries and affluence. Br Med Bull: 2001; 60 33 50
7. Gagliardino J. J., Martella A., Etchegoyen G. S., Caporale J. E., Guidi M. L., Olivera E. M., González C. Hospitalization and re-hospitalization of people with and without diabetes in La Plata, Argentina: comparison of their clinical characteristics and costs. Diabetes Res Clin Pract: 2004; 65 51 59
8. Williams R., Van Gaal L., Lucioni C. CODE-2 Advisory Board Assessing the impact of complications on the costs of type II diabetes. Diabetologia: 2002; 45 S13 S17
9. CDC Diabetes Cost-effectiveness Group Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA: 2002; 287 2542 2551
10. Tuomilehto J., Lindström J., Eriksson J. G., Valle T. T., Hämäläinen H., Ilanne-Parikka P., Keinänen-Kiukaanniemi S., Laakso M., Louheranta A., Rastas M., Salminen V., Uusitupa M. Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med: 2001; 344 1343 1350
11. Knowler W. C., Barrett-Connor E., Fowler S. E., Hamman R. F., Lachin J. M., Walker E. A., Nathan D. M. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med: 2002; 346 393 403
12. Chiasson J. L., Josse R. G., Gomis R., Hanefeld M., Karasik A., Laakso M. STOP-NIDDM Trail Research Group Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet: 2002; 15 2072 2077
13. DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators Gerstein H. C., Yusuf S., Bosch J., Pogue J., Sheridan P., Dinccag N., Hanefeld M., Hoogwerf B., Laakso M., Mohan V., Shaw J., Zinman B., Holman R. R. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet: 2006; 368 1096 1105
14. ADA, American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care: 2013; 36 S67 S74
15. ADA, American Diabetes Association Clinical practice recommendations 2005. Diabetes Care: 2005; 28 S1 S79
16. Butler A. E., Janson J., Bonner-Weir S., Ritzel R., Rizza R. A., Butler P. C. β -Cell deficit and increased β -cell apoptosis in humans with type 2 diabetes. Diabetes: 2003; 52 102 110
17. Samuel V. T., Shulman G. I. Mechanisms for insulin resistance: common threads and missing links. Cell: 2012; 148 852 887
18. Kahn S. E., Prigeon R. L., McCulloch D. K., Boyko E. J., Bergman R. N., Schwartz M. W., Neifing J. L., Ward W. K., Beard J. C., Palmer J. P. Quantification of the relationship between insulin sensitivity and β -cell function in human subjects. Evidence for a hyperbolic function. Diabetes: 1993; 42 1663 1672
19. Ferrannini E., Gastaldelli A., Miyazaki Y., Matsuda M., Mari A., DeFronzo R. A. β -Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab: 2005; 90 493 500
20. Weyer C., Bogardus C., Mott D. M., Pratley R. E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest: 1999; 104 787 794
21. Sakura H., Mizukami H., Yagihashi N., Wada R., Hanyu C., Yagihashi S. Reduced β -cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia: 2002; 45 85 96
22. Araki E., Oyadomari S., Mori M. Impact of endoplasmic reticulum stress pathway on pancreatic β -cells and diabetes mellitus. Exp Biol Med: 2003; 228 1213 1217
23. Bedekar A., Shah K., Koffas M. Natural products for type II diabetes treatment. Adv Appl Microbiol: 2010; 71 21 73
24. Perla V., Jayanty S. S. Biguanide related compounds in traditional antidiabetic functional foods. Food Chem: 2013; 138 1574 1580
25. Nelson-Dooley C., Della-Fera M. A., Hamrick M., Baile C. A. Novel treatments for obesity and osteoporosis: targeting apoptotic pathways in adipocytes. Curr Med Chem: 2005; 12 2215 2225
26. Matsui T., Ueda T., Oki T., Sugita K., Terahara N., Matsumoto K. α -Glucosidase inhibitory action of natural acylated anthocyanins. 1. Survey of natural pigments with potent inhibitory activity. J Agric Food Chem: 2001; 49 1948 1951
27. Schafer A., Hogger P. Oligomeric procyanidins of French maritime pine bark extract (Pycnogenol) effectively inhibit α -glucosidase. Diabetes Res Clin Pract: 2007; 77 41 46
28. Kim Y. M., Jeong Y. K., Wang M. H., Lee W. Y., Rhee H. I. Inhibitory effect of pine extract on α -glucosidase activity and postprandial hyperglycemia. Nutrition: 2005; 21 756 761
29. Liu X., Wei J., Tan F., Zhou S., Würthwein G., Rohdewald P. Antidiabetic effect of Pycnogenol French maritime pine bark extract in patients with diabetes type II. Life Sci: 2004; 75 2505 2513
30. Liu X., Wei J., Tan F., Zhou S., Würthwein G., Rohdewald P. Pycnogenol, French maritime pine bark extract, improves endothelial function of hypertensive patients. Life Sci: 2004; 74 855 862
31. Wehmeier U. F. The biosynthesis and metabolism of acarbose in Actinoplanes sp. SE50/110: A progress report. Biocatal Biotransformation: 2003; 21 279 284
32. Wehmeier U. F., Piepersberg W. Biotechnology and molecular biology of the α -glucosidase inhibitor acarbose. Appl Microbiol Biotechnol: 2004; 63 613 625
33. Matsuo T., Odaka H., Ikeda H. Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes. Am J Clin Nutr: 1992; 55 314S 317S
34. Chen X., Zheng Y., Shen Y. Voglibose (Basen, AO-128), one of the most important α -glucosidase inhibitors. Curr Med Chem: 2006; 13 109 116
35. Chawla R., Thakur P., Chowdhry A., Jaiswal S., Sharma A., Goel R., Sharma J., Priyadarshi S. S., Kumar V., Sharma R. K., Arora R. Evidence based herbal drug standardization approach in coping with challenges of holistic management of diabetes: a dreadful lifestyle disorder of 21st century. J Diabetes Metab Disord: 2013; 12 35
36. Hays N. P., Galassetti P. R., Coker R. H. Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventions. Pharmacol Ther: 2008; 118 181 191
37. Nahas R., Moher M. Complementary and alternative medicine for the treatment of type 2 diabetes. Can Fam Physician: 2009; 55 591 596
38. Patel D. K., Kumar R., Laloo D., Hemalatha S. Diabetes mellitus: an overview on its pharmacological aspects and reported medicinal plants having antidiabetic activity. Asian Pac J Trop Biomed: 2012; 2 411 420
39. Patel D. K., Prasad S. K., Kumar R., Hemalatha S. An overview on antidiabetic medicinal plants having insulin mimetic property. Asian Pac J Trop Biomed: 2012; 2 320 330
40. Chang C. L., Lin Y., Bartolome A. P., Chen Y. C., Chiu S. C., Yang W. C. Herbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compounds. Evid Based Complement Alternat Med: 2013; 2013 378657
41. El-Abhar H. S., Schaalan M. F. Phytotherapy in diabetes: Review on potential mechanistic perspectives. World J Diabetes: 2014; 5 176 197
42. Eddouks M., Bidi A., El Bouhali B., Hajji L., Zeggwagh N. A. Antidiabetic plants improving insulin sensitivity. J Pharm Pharmacol: 2014; 66 1197 1214
43. Jia W., Gao W., Tang L. Antidiabetic herbal drugs officially approved in China. Phytother Res: 2003; 17 1127 1134
44. Shojaii A., Dabaghian F. H., Goushegir A., Fard M. A. Antidiabetic plants of Iran. Acta Med Iran: 2011; 49 637 642
45. Rashidi A. A., Mirhashemi S. M., Taghizadeh M., Sarkhail P. Iranian medicinal plants for diabetes mellitus: a systematic review. Pak J Biol Sci: 2013; 16 401 411
46. Zarshenas M. M., Khademian S., Moein M. Diabetes and related remedies in medieval Persian medicine. Indian J Endocrinol Metab: 2014; 18 142 149
47. Ramírez G., Zavala M., Pérez J., Zamilpa A. In vitro screening of medicinal plants used in Mexico as antidiabetics with glucosidase and lipase inhibitory activities. Evid Based Complement Alternat Med: 2012; 2012 701261
48. Mata R., Cristians S., Escandón-Rivera S., Juárez-Reyes K., Rivero-Cruz I. Mexican antidiabetic herbs: valuable sources of inhibitors of α -glucosidases. J Nat Prod: 2013; 76 468 483
49. Grover J. K., Yadav S., Vats V. Medicinal plants of India with anti-diabetic potential. J Ethnopharmacol: 2002; 81 81 100
50. Mukherjee P. K., Maiti K., Mukherjee K., Houghton P. J. Leads from Indian medicinal plants with hypoglycemic potentials. J Ethnopharmacol: 2006; 106 1 28
51. Hardy M. L., Coulter I., Venuturupalli S., Roth E. A., Favreau J., Morton S. C., Shekelle P. Ayurvedic interventions for diabetes mellitus: a systematic review. Evid Rep Technol Assess (Summ): 2001; 41 2p
52. Zia-ur-rehman M., Mirajab K., Mushtaq A. Potential for Pakistani traditional medicinal plants to combat diabetes. J Tradit Chin Med: 2014; 34 488 490
53. Kadir M. F., Bin Sayeed M. S., Shams T., Mia M. M. Ethnobotanical survey of medicinal plants used by Bangladeshi traditional health practitioners in the management of diabetes mellitus. J Ethnopharmacol: 2012; 144 605 611
54. Kabir M. H., Hasan N., Rahman M. M., Rahman M. A., Khan J. A., Hoque N. T., Bhuiyan M. R., Mou S. M., Jahan R., Rahmatullah M. A survey of medicinal plants used by the Deb barma clan of the Tripura tribe of Moulvibazar district, Bangladesh. J Ethnobiol Ethnomed: 2014; 10 19
55. Marwat S. K., Rehman F., Khan E. A., Khakwani A. A., Ullah I., Khan K. U., Khan I. U. Useful ethnophytomedicinal recipes of angiosperms used against diabetes in South East Asian Countries (India, Pakistan & Sri Lanka). Pak J Pharm Sci: 2014; 27 1338 1358
56. Diallo A., Traore M. S., Keita S. M., Balde M. A., Keita A., Camara M., Van Miert S., Pieters L., Balde A. M. Management of diabetes in Guinean traditional medicine: an ethnobotanical investigation in the coastal lowlands. J Ethnopharmacol: 2012; 144 353 361
57. Lawag I. L., Aguinaldo A. M., Naheed S., Mosihuzzaman M. α -Glucosidase inhibitory activity of selected Philippine plants. J Ethnopharmacol: 2012; 144 217 219
58. Katemo M., Mpiana P. T., Mbala B. M., Mihigo S. O., Ngbolua K. N., Tshibangu D. S., Koyange P. R. Ethnopharmacological survey of plants used against diabetes in Kisangani City (DR Congo). J Ethnopharmacol: 2012; 144 39 43
59. Mootoosamy A., Mahomoodally M. F. Ethnomedicinal application of native remedies used against diabetes and related complications in Mauritius. J Ethnopharmacol: 2014; 151 413 444
60. Picot C. M., Subratty A. H., Mahomoodally M. F. Inhibitory potential of five traditionally used native antidiabetic medicinal plants on α -amylase, α -glucosidase, glucose entrapment, and amylolysis kinetics in vitro. Adv Pharmacol Sci: 2014; 2014 739834
61. Ezuruike U. F., Prieto J. M. The use of plants in the traditional management of diabetes in Nigeria: pharmacological and toxicological considerations. J Ethnopharmacol: 2014; 155 857 924
62. Mohammed A., Ibrahim M. A., Islam M. S. African medicinal plants with antidiabetic potentials: a review. Planta Med: 2014; 80 354 377
63. Jamila F., Mostafa E. Ethnobotanical survey of medicinal plants used by people in Oriental Morocco to manage various ailments. J Ethnopharmacol: 2014; 154 76 87
64. Afifi F. U., Kasabri V. Pharmacological and phytochemical appraisal of selected medicinal plants from Jordan with claimed antidiabetic activities. Sci Pharm: 2013; 81 889 932
65. Bussmann R. W., Paniagua-Zambrana N., Chamorro M. R., Moreira N. M., del Rosario Cuadros Negri M. L., Olivera J. Peril in the market-classification and dosage of species used as anti-diabetics in Lima, Peru. J Ethnobiol Ethnomed: 2013; 9 37
66. Tabatabaei-Malazy O., Larijani B., Abdollahi M. A systematic review of in vitro studies conducted on effect of herbal products on secretion of insulin from Langerhans islets. J Pharm Pharm Sci: 2012; 15 447 466
67. Akshatha V. J., Nalini M. S., D'Souza C., Prakash H. S. Streptomycete endophytes from anti-diabetic medicinal plants of the Western Ghats inhibit α -amylase and promote glucose uptake. Lett Appl Microbiol: 2014; 58 433 439
68. Melzig M. F., Funke I. Pflanzliche Alpha-Amylasehemmer - eine Möglichkeit zur Phytotherapie bei Diabetes Mellitus Typ II? Wien Med Wochenschr: 2007; 157 320 324
69. Rahimzadeh M., Jahanshahi S., Moein S., Moein M. R. Evaluation of alpha-amylase inhibition by Urtica dioica and Juglans regia extracts. Iran J Basic Med Sci: 2014; 17 465 469
70. Li Y., Chen Y., Xiao C., Chen D., Xiao Y., Mei Z. Rapid screening and identification of α -amylase inhibitors from Garcinia xanthochymus using enzyme-immobilized magnetic nanoparticles coupled with HPLC and MS. J Chromatogr B Analyt Technol Biomed Life Sci: 2014; 960 166 173
71. Wilcox G. Review article insulin and insulin resistance. Clin Biochem Rev: 2005; 26 19 39
72. Sangeetha M. K., Priya C. D., Vasanthi H. R. Anti-diabetic property of Tinospora cordifolia and its active compound is mediated through the expression of Glut-4 in L6 myotubes. Phytomedicine: 2013; 20 246 248
73. Kadan S., Saad B., Sasson Y., Zaid H. In vitro evaluations of cytotoxicity of eight antidiabetic medicinal plants and their effect on GLUT4 Translocation. Evid Based Complement Alternat Med: 2013; 2013 549345
74. Berger J., Moller D. E. The mechanisms of action of PPARs. Annu Rev Med: 2002; 53 409 435
75. Wang L., Waltenberger B., Pferschy-Wenzig E. M., Blunder M., Liu X., Malainer C., Blazevic T., Schwaiger S., Rollinger J. M., Heiss E. H., Schuster D., Kopp B., Bauer R., Stuppner H., Dirsch V. M., Atanasov A. G. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPAR γ): a review. Biochem Pharmacol: 2014; 92 73 89
76. Katz S. R., Newman R. A., Lansky E. P. Punica granatum: heuristic treatment for diabetes mellitus. J Med Food: 2007; 10 213 217
77. Gaur R., Yadav K. S., Verma R. K., Yadav N. P., Bhakuni R. S. In vivo anti-diabetic activity of derivatives of isoliquiritigenin and liquiritigenin. Phytomedicine: 2014; 21 415 422
78. Lv X. F., Meng Q. Y., Guo X. M. Effect of Rehmannia glutinosa water extraction on insulin resistance and gene expression of resistin in type 2 diabetes mellitus rats. Zhongguo Zhong Yao Za Zhi: 2007; 32 2182 2184
79. Seo J. B., Choe S. S., Jeong H. W., Park S. W., Shin H. J., Choi S. M., Park J. Y., Choi E. W., Kim J. B., Seen D. S., Jeong J. Y., Lee T. G. Anti-obesity effects of Lysimachia foenum-graecum characterized by decreased adipogenesis and regulated lipid metabolism. Exp Mol Med: 2011; 43 205 215
80. Kim Y. J., Choi M. S., Park Y. B., Kim S. R., Lee M. K., Jung U. J. Garcinia cambogia attenuates diet-induced adiposity but exacerbates hepatic collagen accumulation and inflammation. World J Gastroenterol: 2013; 19 4689 4701
81. Ilavenil S., Arasu M. V., Lee J. C., Kim da H., Roh S. G., Park H. S., Choi G. J., Mayakrishnan V., Choi K. C. Trigonelline attenuates the adipocyte differentiation and lipid accumulation in 3T3-L1 cells. Phytomedicine: 2014; 21 758 765
82. Kim H. S., Sung H. Y., Kim M. S., Kim J. L., Kang M. K., Gong J. H., Park H. S., Kang Y. H. Oleanolic acid suppresses resistin induction in adipocytes by modulating Tyk-STAT signaling. Nutr Res: 2013; 33 144 153
83. Mauricio D. Inhibidores SGLT-2: de la corteza del manzano y la glucosuria familiar al tratamiento de la diabetes mellitus tipo 2. Med Clin (Barc): 2013; 141 02 S31 S35
84. Makarova E., Górnas̈ P., Konrade I., Tirzite D., Cirule H., Gulbe A., Pugajeva I., Seglina D., Dambrova M. Acute anti-hyperglycaemic effects of an unripe apple preparation containing phlorizin in healthy volunteers: a preliminary study. J Sci Food Agric: 2015; 95 560 568
85. Chao E. C., Henry R. R. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov: 2010; 9 551 559
86. Yabe D., Seino Y. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation. Prog Biophys Mol Biol: 2011; 107 248 256
87. Cernea S., Raz I. Therapy in the early stage: incretins. Diabetes Care: 2011; 34 02 S264 S271
88. Kosaraju J., Dubala A., Chinni S., Khatwal R. B., Satish Kumar M. N., Basavan D. A molecular connection of Pterocarpus marsupium, Eugenia jambolana and Gymnema sylvestre with dipeptidyl peptidase-4 in the treatment of diabetes. Pharm Biol: 2014; 52 268 271
89. Saleem S., Jafri L., Haq I. U., Chee Chang L., Calderwood D., Green B. D., Mirza B. Plants Fagonia cretica L. and Hedera nepalensis K. Koch contain natural compounds with potent dipeptidyl peptidase-4 (DPP-4) inhibitory activity. J Ethnopharmacol: 2014; 1156 26 36
90. Wang P., Alvarez-Perez J. C., Felsenfeld D. P., Liu H., Sivendran S., Bender A., Kumar A., Sanchez R., Scott D. K., Garcia-Ocaña A., Stewart A. F. A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication. Nat Med: 2015; 21 383 388
91. Combs A. P. Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer. J Med Chem: 2010; 53 2333 2344
92. Uddin M. N., Sharma G., Yang J. L., Choi H. S., Lim S. I., Kang K. W., Oh W. K. Oleanane triterpenes as protein tyrosine phosphatase 1B (PTP1B) inhibitors from Camellia japonica. Phytochemistry: 2014; 103 99 106
93. Pitschmann A., Zehl M., Atanasov A. G., Dirsch V. M., Heiss E., Glasl S. Walnut leaf extract inhibits PTP1B and enhances glucose-uptake in vitro. J Ethnopharmacol: 2014; 152 599 602
94. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ Res: 2010; 107 1058 1070
95. Halliwell B. Free radicals and antioxidants: updating a personal view. Nutr Rev: 2012; 70 257 265
96. Palma H. E., Wolkmer P., Gallio M., Corrêa M. M., Schmatz R., Thomé G. R., Pereira L. B., Castro V. S., Pereira A. B., Bueno A., de Oliveira L. S., Rosolen D., Mann T. R., de Cecco B. S., Graça D. L., Lopes S. T., Mazzanti C. M. Oxidative stress parameters in blood, liver, and kidney of diabetic rats treated with curcumin and/or insulin. Mol Cell Biochem: 2014; 386 199 210
97. Manzari-Tavakoli A., Pouraboli I., Yaghoobi M. M., Mehrabani M., Mirtadzadini S. M. Antihyperglycemic, antilipid peroxidation, and insulin secretory activities of Otostegia persica shoot extract in streptozotocin-induced diabetic rats and in vitro C187 pancreatic β -cells. Pharm Biol: 2013; 51 253 259
98. Ha U. S., Bae W. J., Kim S. J., Yoon B. I., Jang H., Hong S. H., Lee J. Y., Hwang S. Y., Kim S. W. Protective effect of cyanidin-3-O- β -D-glucopyranoside fraction from mulberry fruit pigment against oxidative damage in streptozotocin-induced diabetic rat bladder. Neurourol Urodyn: 2013; 32 493 499
99. Talukder F. Z., Khan K. A., Uddin R., Jahan N., Alam M. A. In vitro free radical scavenging and anti-hyperglycemic activities of Achyranthes aspera extract in alloxan-induced diabetic mice. Drug Discov Ther: 2012; 6 298 305
100. Teugwa C. M., Mejiato P. C., Zofou D., Tchinda B. T., Boyom F. F. Antioxidant and antidiabetic profiles of two African medicinal plants: Picralima nitida (Apocynaceae) and Sonchus oleraceus (Asteraceae). BMC Complement Altern Med: 2013; 13 175
101. El-Amin M., Virk P., Elobeid M. A., Almarhoon Z. M., Hassan Z. K., Omer S. A., Merghani N. M., Daghestani M. H., Al-Olayan E. M. Anti-diabetic effect of Murraya koenigii (L) and Olea europaea (L) leaf extracts on streptozotocin induced diabetic rats. Pak J Pharm Sci: 2013; 26 359 365
102. Li Z., Geng Y. N., Jiang J. D., Kong W. J. Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid Based Complement Alternat Med: 2014; 2014 289264
103. Castro M. C., Massa M. L., Schinella G., Gagliardino J. J., Francini F. Lipoic acid prevents liver metabolic changes induced by administration of a fructose-rich diet. Biochim Biophys Acta: 2013; 1830 2226 2232
104. Castro M. C., Francini F., Schinella G., Caldiz C. I., Zubiria M. G., Gagliardino J. J., Massa M. L. Apocynin administration prevents the changes induced by a fructose-rich diet on rat liver metabolism and the antioxidant system. Clin Sci (Lond): 2012; 123 681 692
105. Li Z. Q., Chang H. J., Sang W. F. Clinical efficacy of special effect san xiao decoction on type 2 diabetes mellitus. Zhong Yao Cai: 2013; 36 163 166
106. Sengupta K., Mishra A. T., Rao M. K., Sarma K. V., Krishnaraju A. V., Trimurtulu G. Efficacy and tolerability of a novel herbal formulation for weight management in obese subjects: a randomized double blind placebo controlled clinical study. Lipids Health Dis: 2012; 11 122
107. Ghorbani A. Clinical and experimental studies on polyherbal formulations for diabetes: current status and future prospective. J Integr Med: 2014; 12 336 345
108. Moona M. M., Smits R., Kertesz J., Meyer A., Mackler L. Clinical inquiry: do complementary agents lower HbA1c when used with standard type 2 diabetes therapy? J Fam Pract: 2014; 63 336 338
109. Vogler B. K., Ernst E. Aloe vera: a systematic review of its clinical effectiveness. Br J Gen Pract: 1999; 49 823 828
110. Devaraj S., Yimam M., Brownell L. A., Jialal I., Singh S., Jia Q. Effects of Aloe vera supplementation in subjects with prediabetes/metabolic syndrome. Metab Syndr Relat Disord: 2013; 11 35 40
111. Choi H. C., Kim S. J., Son K. Y., Oh B. J., Cho B. L. Metabolic effects of Aloe vera gel complex in obese prediabetes and early non-treated diabetic patients: randomized controlled trial. Nutrition: 2013; 29 1110 1114
112. Stohs S. J., Miller H., Kaats G. R. A review of the efficacy and safety of banaba (Lagerstroemia speciosa L.) and corosolic acid. Phytother Res: 2012; 26 317 324
113. Leung L., Birtwhistle R., Kotecha J., Hannah S., Cuthbertson S. Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a mini review. Br J Nutr: 2009; 102 1703 1708
114. Chuang C. Y., Hsu C., Chao C. Y., Wein Y. S., Kuo Y. H., Huang C. J. Fractionation and identification of 9c,11 t,13 t-conjugated linolenic acid as an activator of PPAR α in bitter gourd (Momordica charantia L.). J Biomed Sci: 2006; 13 763 772
115. Yibchok-Anun S., Adisakwattana S., Yao C. Y., Sangvanich P., Roengsumran S., Hsu W. H. Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities. Biol Pharm Bull: 2006; 29 1126 1131
116. Ooi C. P., Yassin Z., Hamid T. A. Momordica charantia for type 2 diabetes mellitus. Cochrane Database Syst Rev: 2010; 2 CD007845
117. Ooi C. P., Yassin Z., Hamid T. A. Momordica charantia for type 2 diabetes mellitus. Cochrane Database Syst Rev: 2012; 8 CD007845
118. Medagama A. B., Bandara R. The use of complementary and alternative medicines (CAMs) in the treatment of diabetes mellitus: is continued use safe and effective? Nutr J: 2014; 13 102
119. Huseini H. F., Hasani-Rnjbar S., Nayebi N., Heshmat R., Sigaroodi F. K., Ahvazi M., Alaei B. A., Kianbakht S. Capparis spinosa L. (Caper) fruit extract in treatment of type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. Complement Ther Med: 2013; 21 447 452
120. Khan A., Bryden N. A., Polansky M. M., Anderson R. A. Insulin potentiating factor and chromium content of selected foods and spices. Biol Trace Elem Res: 1990; 24 183 188
121. Broadhurst C. L., Polansky M. M., Anderson R. A. Insulin-like biological activity of culinary and medicinal plant aqueous extracts in vitro. J Agric Food Chem: 2000; 48 849 852
122. Jarvill-Taylor K. J., Anderson R. A., Graves D. J. A hydroxychalcone derived from cinnamon functions as a mimetic for insulin in 3T3-L1 adipocytes. J Am Coll Nutr: 2001; 20 327 336
123. Qin B., Nagasaki M., Ren M., Bajotto G., Oshida Y., Sato Y. Cinnamon extract (traditional herb) potentiates in vivo insulin-regulated glucose utilization via enhancing insulin signaling in rats. Diabetes Res Clin Pract: 2003; 62 139 148
124. Gruenwald J., Freder J., Armbruester N. Cinnamon and health. Crit Rev Food Sci Nutr: 2010; 50 822 834
125. Anderson R. A., Broadhurst C. L., Polansky M. M., Schmidt W. F., Khan A., Flanagan V. P., Schoene N. W., Graves D. J. Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. J Agric Food Chem: 2004; 52 65 70
126. Khan A., Safdar M., Ali Khan M. M., Khattak K. N., Anderson R. A. Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care: 2003; 26 3215 3218
127. Vanschoonbeek K., Thomassen B. J., Senden J. M., Wodzig W. K., van Loon L. J. Cinnamon supplementation does not improve glycemic control in postmenopausal type 2 diabetes patients. J Nutr: 2006; 136 977 980
128. Pham A. Q., Kourlas H., Pham D. Q. Cinnamon supplementation in patients with type 2 diabetes mellitus. Pharmacotherapy: 2007; 27 595 599
129. Kirkham S., Akilen R., Sharma S., Tsiami A. The potential of cinnamon to reduce blood glucose levels in patients with type 2 diabetes and insulin resistance. Diabetes Obes Metab: 2009; 11 1100 1113
130. Davis P. A., Yokoyama W. Cinnamon intake lowers fasting blood glucose: meta-analysis. J Med Food: 2011; 14 884 889
131. Leach M. J., Kumar S. Cinnamon for diabetes mellitus. Cochrane Database Syst Rev: 2012; 9 CD007170
132. Akilen R., Tsiami A., Devendra D., Robinson N. Cinnamon in glycaemic control: Systematic review and meta analysis. Clin Nutr: 2012; 31 609 615
133. Andújar I., Recio M. C., Giner R. M., Ríos J. L. Cocoa polyphenols and their potential benefits for human health. Oxid Med Cell Longev: 2012; 2012 906252
134. Latif R. Chocolate/cocoa and human health: a review. Neth J Med: 2013; 71 63 68
135. Grassi D., Desideri G., Necozione S., Lippi C., Casale R., Properzi G., Blumberg J. B., Ferri C. Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. J Nutr: 2008; 138 1671 1676
136. Hooper L., Kay C., Abdelhamid A., Kroon P. A., Cohn J. S., Rimm E. B., Cassidy A. Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-analysis of randomized trials. Am J Clin Nutr: 2012; 95 740 751
137. Kim J. A., Montagnani M., Koh K. K., Quon M. J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation: 2006; 113 1888 1904
138. Salazar-Martínez E., Willett W. C., Ascherio A., Manson J. E., Leitzmann M. F., Stampfer M. J., Hu F. B. Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med: 2004; 140 1 8
139. Pereira M. A., Parker E. D., Folsom A. R. Coffee consumption and risk of type 2 diabetes mellitus: an 11-year prospective study of 28812 postmenopausal women. Arch Intern Med: 2006; 166 1311 1316
140. Basch E., Ulbricht C., Kuo G., Szapary P., Smith M. Therapeutic applications of fenugreek. Altern Med Rev: 2003; 8 20 27
141. Haber S. L., Keonavong J. Fenugreek use in patients with diabetes mellitus. Am J Health Syst Pharm: 2013; 70 1196 1203
142. Yadav U. C., Baquer N. Z. Pharmacological effects of Trigonella foenum-graecum L. in health and disease. Pharm Biol: 2014; 52 243 254
143. Swaroop A., Bagchi M., Kumar P., Preuss H. G., Tiwari K., Marone P. A., Bagchi D. Safety, efficacy and toxicological evaluation of a novel, patented anti-diabetic extract of Trigonella foenum-fraecum seed extract (Fenfuro). Toxicol Mech Methods: 2014; 24 495 503
144. Neelakantan N., Narayanan M., de Souza R. J., van Dam R. M. Effect of fenugreek (Trigonella foenum-graecum L.) intake on glycemia: a meta-analysis of clinical trials. Nutr J: 2014; 13 7
145. Zhou J., Chan L., Zhou S. Trigonelline: a plant alkaloid with therapeutic potential for diabetes and central nervous system disease. Curr Med Chem: 2012; 19 3523 3531
146. Ackermann R. T., Mulrow C. D., Ramirez G., Gardner C. D., Morbidoni L., Lawrence V. A. Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med: 2001; 161 813 824
147. Mohammadi A., Oshaghi E. A. Effect of garlic on lipid profile and expression of LXR alpha in intestine and liver of hypercholesterolemic mice. J Diabetes Metab Disord: 2014; 13 20
148. Gutiérrez R. M., Mitchell S., Solis R. V. Psidium guajava: a review of its traditional uses, phytochemistry and pharmacology. J Ethnopharmacol: 2008; 117 1 27
149. Tiwari P., Mishra B. N., Sangwan N. S. Phytochemical and pharmacological properties of Gymnema sylvestre: an important medicinal plant. Biomed Res Int: 2014; 2014 830285
150. Di Fabio G., Romanucci V., Zarrelli M., Giordano M., Zarrelli A. C-4 gem-dimethylated oleanes of Gymnema sylvestre and their pharmacological activities. Molecules: 2013; 18 14892 14919
151. Alqahtani A., Hamid K., Kam A., Wong K. H., Abdelhak Z., Razmovski-Naumovski V., Chan K., Li K. M., Groundwater P. W., Li G. Q. The pentacyclic triterpenoids in herbal medicines and their pharmacological activities in diabetes and diabetic complications. Curr Med Chem: 2013; 20 908 931
152. Kumar S. N., Mani U. V., Mani I. An open label study on the supplementation of Gymnema sylvestre in type 2 diabetics. J Diet Suppl: 2010; 7 273 282
153. Dar S. A., Ganai F. A., Yousuf A. R., Balkhi M. U., Bhat T. M., Sharma P. Pharmacological and toxicological evaluation of Urtica dioica. Pharm Biol: 2013; 51 170 180
154. Rau O., Wurglics M., Dingermann T., Abdel-Tawab M., Schubert-Zsilavecz M. Screening of herbal extracts for activation of the human peroxisome proliferator-activated receptor. Pharmazie: 2006; 61 952 956
155. Kianbakht S., Khalighi-Sigaroodi F., Dabaghian F. H. Improved glycemic control in patients with advanced type 2 diabetes mellitus taking Urtica dioica leaf extract: a randomized double-blind placebo-controlled clinical trial. Clin Lab: 2013; 59 1071 1076
156. Kianbakht S., Dabaghian F. H. Improved glycemic control and lipid profile in hyperlipidemic type 2 diabetic patients consuming Salvia officinalis L. leaf extract: a randomized placebo. Controlled clinical trial. Complement Ther Med: 2013; 21 441 446
157. Eidi M., Eidi A., Zamanizadeh H. Effect of Salvia officinalis L. leaves on serum glucose and insulin in healthy and streptozocin-induced diabetic rats. J Ethnopharmacol: 2005; 100 310 313
158. Lima C. F., Azevedo M. F., Araujo R., Fernandes-Ferreira M., Pereira-Wilson C. Metformine-like effect of Salvia officinalis (common sage): is it useful in diabetes prevention? Br J Nutr: 2006; 96 326 333
159. Sa C. M., Ramos A. A., Azevedo M. F., Lima C. F., Fernandes-Ferreira M., Pereira-Wilson C. Sage tea drinking improves lipid profile and antioxidant defenses in humans. Int J Mol Sci: 2009; 10 3937 3950
160. Kianbakht S., Abasi B., Perham M., Hashem Dabaghian F. Antihyperlipidemic effects of Salvia officinalis L. leaf extract in patients with hyperlipidemia: a randomized double blind placebo-controlled clinical trial. Phytother Res: 2011; 25 1849 1853
161. Choi S. B., Jang J. S., Park S. Estrogen and exercise may enhance beta-cell function and mass via insulin receptor substrate 2 induction in ovariectomized diabetic rats. Endocrinology: 2005; 146 4786 4794
162. Kwon D. Y., Daily J. W. 3rd, Kim H. J., Park S. Antidiabetic effects of fermented soybean products on type 2 diabetes. Nutr Res: 2010; 30 1 13
163. Zhang Y. B., Chen W. H., Guo J. J., Fu Z. H., Yi C., Zhang M., Na X. L. Soy isoflavone supplementation could reduce body weight and improve glucose metabolism in non-Asian postmenopausal women-a meta-analysis. Nutrition: 2013; 29 8 14
164. Khan N., Mukhtar H. Tea and health: studies in humans. Curr Pharm Des: 2013; 19 6141 6147
165. Song Y., Manson J. E., Buring J. E., Sesso H. D., Liu S. Associations of dietary flavonoids with risk of type 2 diabetes, and markers of insulin resistance and systemic inflammation in women: a prospective study and cross-sectional analysis. J Am Coll Nutr: 2005; 24 376 384
166. Iso H., Date C., Wakai K., Fukui M., Tamakoshi A. The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults. Ann Intern Med: 2006; 144 554 562
167. Neyestani T. R., Shariatzade N., Kalayi A., Gharavi A., Khalaji N., Dadkhah M., Zowghi T., Haidari H., Shab-bidar S. Regular daily intake of black tea improves oxidative stress biomarkers and decreases serum C-reactive protein levels in type 2 diabetic patients. Ann Nutr Metabol: 2010; 57 40 49
168. Nagao T., Meguro S., Hase T., Otsuka K., Komikado M., Tokimitsu I., Yamamoto T., Yamamoto K. A catechin-rich beverage improves obesity and blood glucose control in patients with type 2 diabetes. Obesity (Silver Spring): 2009; 17 310 317
169. Aggarwal B. B., Yuan W., Li S., Gupta S. C. Curcumin-free turmeric exhibits anti-inflammatory and anticancer activities: Identification of novel components of turmeric. Mol Nutr Food Res: 2013; 57 1529 1542
170. Gupta S. C., Sung B., Kim J. H., Prasad S., Li S., Aggarwal B. B. Multitargeting by turmeric, the golden spice: From kitchen to clinic. Mol Nutr Food Res: 2013; 57 1510 1528
171. Wickenberg J., Ingemansson S. L., Hlebowicz J. Effects of Curcuma longa (turmeric) on postprandial plasma glucose and insulin in healthy subjects. Nutr J: 2010; 9 43
172. Khajehdehi P., Pakfetrat M., Javidnia K., Azad F., Malekmakan L., Nasab M. H., Dehghanzadeh G. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor- β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scand J Urol Nephrol: 2011; 45 365 370
173. Aldebasi Y. H., Aly S. M., Rahmani A. H. Therapeutic implications of curcumin in the prevention of diabetic retinopathy via modulation of anti-oxidant activity and genetic pathways. Int J Physiol Pathophysiol Pharmacol: 2013; 5 194 202
174. Maradana M. R., Thomas R., O'Sullivan B. J. Targeted delivery of curcumin for treating type 2 diabetes. Mol Nutr Food Res: 2013; 57 1550 1556
175. Hosseini S., Huseini H. F., Larijani B., Mohammad K., Najmizadeh A., Nourijelyani K., Jamshidi L. The hypoglycemic effect of Juglans regia leaves aqueous extract in diabetic patients: A first human trial. Daru: 2014; 22 19
176. Jelodar G., Mohsen M., Shahram S. Effect of walnut leaf, coriander and pomegranate on blood glucose and histopathology of pancreas of alloxan induced diabetic rats. Afr J Tradit Complement Altern Med: 2007; 43 299 305
177. Asgary S., Parkhideh S., Solhpour A., Madani H., Mahzouni P., Rahimi P. Effect of ethanolic extract of Juglans regia L. on blood sugar in diabetes-induced rats. J Med Food: 2008; 11 533 538
178. Mohammadi J., Sadeqpour K., Delaviz H., Mohammadi B. Anti-diabetic effects of an alcoholic extract of Juglans regia in an animal model. Turk J Med Sci: 2011; 41 685 691
179. Hosseini S., Jamshidi L., Mehrzadi S., Mohammad K., Najmizadeh A. R., Alimoradi H., Huseini H. F. Effects of Juglans regia L. leaf extract on hyperglycemia and lipid profiles in type two diabetic patients: a randomized double-blind, placebo-controlled clinical trial. J Ethnopharmacol: 2014; 152 451 456
180. Ahmad H., Khan I., Wahid A. Antiglycation and antioxidation properties of Juglans regia and Calendula officinalis: possible role in reducing diabetic complications and slowing down ageing. J Tradit Chin Med: 2012; 32 411 414
181. Heck C. I., de Mejia E. G. Yerba Mate Tea (Ilex paraguariensis): a comprehensive review on chemistry, health implications, and technological considerations. J Food Sci: 2007; 72 R138 R151
182. Bracesco N., Sánchez A. G., Contreras V., Menini T., Gugliucci A. Recent advances on Ilex paraguariensis research: minireview. J Ethnopharmacol: 2011; 136 378 384
183. Schinella G., Neyret E., Cónsole G., Tournier H., Prieto J. M., Ríos J. L., Giner R. M. An aqueous extract of Ilex paraguariensis reduces carrageenan-induced edema and inhibits the expression of cyclooxygenase-2 and inducible nitric oxide synthase in animal models of inflammation. Planta Med: 2014; 80 961 968
184. Oliveira D. M., Freitas H. S., Souza M. F., Arçari D. P., Ribeiro M. L., Carvalho P. O., Bastos D. H. Yerba Maté (Ilex paraguariensis) aqueous extract decreases intestinal SGLT1 gene expression but does not affect other biochemical parameters in alloxan-diabetic Wistar rats. J Agric Food Chem: 2008; 56 10527 10532
185. Kang Y. R., Lee H. Y., Kim J. H., Moon D. I., Seo M. Y., Park S. H., Choi K. H., Kim C. R., Kim S. H., Oh J. H., Cho S. W., Kim S. Y., Kim M. G., Chae S. W., Kim O., Oh H. G. Anti-obesity and anti-diabetic effects of Yerba Mate (Ilex paraguariensis) in C57BL/6J mice fed a high-fat diet. Lab Anim Res: 2012; 28 23 29
186. Arçari D. P., Bartchewsky W. jr., dos Santos T. W., Oliveira K. A., DeOliveira C. C., Gotardo É M., Pedrazzoli J. jr., Gambero A., Ferraz L. F., Carvalho Pde O., Ribeiro M. L. Anti-inflammatory effects of yerba maté extract (Ilex paraguariensis) ameliorate insulin resistance in mice with high fat diet-induced obesity. Mol Cell Endocrinol: 2011; 335 110 115
187. Pereira D. F., Kappel V. D., Cazarolli L. H., Boligon A. A., Athayde M. L., Guesser S. M., Da Silva E. L., Silva F. R. Influence of the traditional Brazilian drink Ilex paraguariensis tea on glucose homeostasis. Phytomedicine: 2012; 19 868 877
188. Kahn S. E., Hull R. L., Utzschneider K. M. Review article mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature: 2006; 444 840 846
189. De Morais E. C., Stefanuto A., Klein G. A., Boaventura B. C., de Andrade F., Wazlawik E., Di Pietro P. F., Maraschin M., da Silva E. L. Consumption of yerba mate (Ilex paraguariensis) improves serum lipid parameters in healthy dyslipidemic subjects and provides an additional LDL-cholesterol reduction in individuals on statin therapy. J Agric Food Chem: 2009; 57 8316 8324
190. Klein G. A., Stefanuto A., Boaventura B. C., de Morais E. C., Cavalcante Lda S., de Andrade F., Wazlawik E., Di Pietro P. F., Maraschin M., da Silva E. L. Mate tea (Ilex paraguariensis) improves glycemic and lipid profiles of type 2 diabetes and pre-diabetes individuals: a pilot study. J Am Coll Nutr: 2011; 30 320 332
191. Bremer Boaventura C., Faria Di Pietro P., Klein G. A., Stefanuto A., de Morais E. C., de Andrade F., Wazlawika E., da Silva E. L. Antioxidant potential of mate tea (Ilex paraguariensis) in type 2 diabetic mellitus and pre-diabetic individuals. J Funct Foods: 2013; 5 1057 1064
192. Anuradha C. V. Phytochemicals targeting genes relevant for type 2 diabetes. Can J Physiol Pharmacol: 2013; 91 397 411
193. Suhitha S., Gunasekaran K., Velmurugan D. Structure based design of compounds from natural sources for diabetes and inflammation. Bioinformation: 2012; 8 1125 1131
194. Vanaclocha B., Risco E., Cañigueral S. Interacciones entre preparados vegetales y fármaos de sínteis: revisión de las monografías de la EMA y ESCOP. Rev Fitoter: 2014; 14 5 36
195. Bratman S., Girman A. M. Mosby's handbook of herbs and supplements and their therapeutic uses. St. Louis Mosby Health Gate: 2003
196. Harkness R., Bratman S. Mosby's handbook of drug-herb and drug-supplement interactions. St. Louis Mosby Health Gate: 2003
197. Ríos J. L. Fitoterapia. Valencia (Spain) Publicaciones Universitat de Valencia: 2009